<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964338</url>
  </required_header>
  <id_info>
    <org_study_id>TV48125-CNS-30057</org_study_id>
    <secondary_id>2016-003171-21</secondary_id>
    <nct_id>NCT02964338</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products, R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the current study is to evaluate the efficacy and safety of TEV-48125
      (Fremanezumab), in the prevention of CCH in adult patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2016</start_date>
  <completion_date type="Anticipated">November 6, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 9, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean change from baseline (run-in period) in the monthly average number of cluster headache (CH) attacks during the 12-week period after administration of the first dose</measure>
    <time_frame>Week 0 to 12</time_frame>
    <description>The primary efficacy endpoint of this study is the mean change from baseline (run-in period) in the monthly average number of cluster headache (CH) attacks during the 12-week period after administration of the first dose of the investigational medicinal product (IMP), ie, based on week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with a ≥50% reduction from baseline (run-in period) in the monthly average number of CH attacks over the 12-week period after the administration of the first dose</measure>
    <time_frame>Week 0 to 12</time_frame>
    <description>The proportion of patients with a ≥50% reduction from baseline (run-in period) in the monthly average number of CH attacks over the 12-week period after the administration of the first dose of the IMP, ie, based on week 0 to 12 data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change from baseline in the number of CH attacks during the 12-week period after administration of the first dose</measure>
    <time_frame>Week 0 to 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Cluster Headache</condition>
  <arm_group>
    <arm_group_label>Fremanezumab- A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug Regimen 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fremanezumab- B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug Regimen 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fremanezumab- A</intervention_name>
    <arm_group_label>Fremanezumab- A</arm_group_label>
    <other_name>TEV-48125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fremanezumab- B</intervention_name>
    <arm_group_label>Fremanezumab- B</arm_group_label>
    <other_name>TEV-48125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has a history of CCH according to the International Classification of
             Headache Disorders - 3 beta criteria (Headache Classification Committee of the IHS
             2013) for ≥12 months prior to screening

          -  The patient has a total body weight of ≥45 kg (99 lbs.)

          -  The patient is in good health in the opinion of the investigator

          -  Women of childbearing potential (WOCBP) whose male partners are potentially fertile
             (ie, no vasectomy) must use highly effective birth control methods for the duration of
             the study

          -  Men must be sterile, or if they are potentially fertile/reproductively competent (not
             surgically [eg, vasectomy] or congenitally sterile) and their female partners are of
             childbearing potential, must agree to use, together with their female partners,
             acceptable birth control

          -  If a patient is receiving Botox, it should be in a stable dose regimen, considered as
             having ≥2 cycles of Botox prior to screening. The patient should not receive Botox
             during the run-in period up to the evaluation period (12 weeks) where the primary
             endpoint is evaluated.

               -  Additional criteria apply, please contact the investigator for more information

        Exclusion Criteria:

          -  The patient has used systemic steroids for any medical reason (including treatment of
             the current CH cycle within ≤7 days prior to screening The patient has used an
             intervention/device (eg, scheduled nerve blocks) for headache during the 4 weeks prior
             to screening.

          -  The patient has clinically significant hematological, renal, endocrine, immunologic,
             pulmonary, gastrointestinal, genitourinary, cardiovascular, neurologic, hepatic, or
             ocular disease at the discretion of the investigator.

          -  The patient has evidence or medical history of clinically significant psychiatric
             issues determined at the discretion of the investigator.

          -  The patient has a past or current history of cancer or malignant tumor in the past 5
             years, except for appropriately treated non-melanoma skin carcinoma.

          -  The patient is pregnant or lactating.

          -  The patient has a history of hypersensitivity reactions to injected proteins,
             including monoclonal antibodies.

          -  The patient has participated in a clinical study of a monoclonal antibody within 3
             months or 5 half-lives before administration of the first dose of the IMP, whichever
             is longer, unless it is known that the patient received placebo during the study.

          -  The patient has a history of prior exposure to a monoclonal antibody targeting the
             calcitonin gene-related peptide (CGRP) pathway (AMG 334, ALD304, LY2951742, or
             fremanezumab). If patient has participated in a clinical study with any of these
             monoclonal antibodies, it has to be confirmed that the patient received placebo in
             order to be eligible for this study.

          -  The patient is an employee of the sponsor/participating study center who is directly
             involved in the study or is the relative of such an employee.

          -  The patient has an active implant for neurostimulation used in the treatment of CH.

          -  The patient is a member of a vulnerable population (eg, people kept in detention).

          -  The patient has a history of alcohol abuse prior to screening and/or drug abuse that
             in the investigator's opinion could interfere with the study evaluations or the
             patient's safety .

               -  Additional criteria apply, please contact the investigator for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teva U.S. Medical Information</last_name>
    <phone>1-888-483-8279</phone>
    <email>USMedInfo@tevapharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Teva Investigational Site 13819</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>818-312-9101</phone>
      <email>haazami@clin-edge.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13811</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-315-1456</phone>
      <email>dbkudrow@earthlink.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13823</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-723-5184</phone>
      <email>nhindiye@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13837</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>720-474-3217</phone>
      <email>marius.birlea@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13814</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>719-262-9283</phone>
      <email>kroberson@deltawaves.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13836</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>303-842-1227</phone>
      <email>alexander.feldman@scientiamr.com ; info@scientiamr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13813</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>303-357-5443</phone>
      <email>corimillen@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13821</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510-2483</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-785-4085</phone>
      <email>chris.gottschalk@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13812</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-914-1900</phone>
      <email>peter@neinh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13810</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>352-333-0094</phone>
      <email>drj@ehsfamily.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13829</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>386-676-6340</phone>
      <email>neurojscott@yahoo.com; neurosgeyer@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13830</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>727-548-6100</phone>
      <email>drellis@fmpm.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13840</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>813-877-8839</phone>
      <email>chuffman@meridienresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34222</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 151 529 5666</phone>
      <email>nicholas.silver@thewaltoncentre.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13833</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>706-653-8455</phone>
      <email>jliss@iacthealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13838</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>912-790-4837</phone>
      <email>mhemphill@mcrmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13826</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>773-388-6390</phone>
      <email>afeoktistov@diamondheadache.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13818</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>734-677-6000</phone>
      <email>jrs@mhni.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13832</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>702-749-7147</phone>
      <email>nagyaj@nvhi.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13831</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 304 598-4000 (75656)</phone>
      <email>dwatson@hsc.wvu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13820</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1-609-921-3555 (20)</phone>
      <email>jtapter@gminstitutes.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13827</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>505-224-7407</phone>
      <email>msalazar@abqct.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13816</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>716-250-2000</phone>
      <email>lmechtler@dentinstitute.com; lmechtle@buffalo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13817</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ms3006@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13809</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>919-781-2514</phone>
      <email>sjagadeesan@wakeresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13839</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 (704) 638-9000 (4505)</phone>
      <email>mital.dalsania@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13825</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>216-445-3616</phone>
      <email>stillmm@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13824</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-955-2243</phone>
      <email>michael.marmura@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13841</name>
      <address>
        <city>Richmond</city>
        <state>Texas</state>
        <zip>77307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 1 832 500 5185</phone>
      <email>drsatija@dmmsinc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13822</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>757-233-9280</phone>
      <email>ghaase@timresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 78120</name>
      <address>
        <city>Auchenflower</city>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 737 211 523</phone>
      <email>jtodhunter@wesleyresearch.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 78118</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 459 982 523</phone>
      <email>meller76@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 78123</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 3 9342 4426</phone>
      <email>obrientj@unimelb.edu.au; t.obrien@aldred.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 78122</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 3 9342 4426</phone>
      <email>obrientj@unimelb.edu.au; t.obrien@aldred.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 78121</name>
      <address>
        <city>Randwick</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>a.zagami@unsw.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11130</name>
      <address>
        <city>Calgary</city>
        <zip>T3M 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1-403-956-2462</phone>
      <email>farnaz.amoozegar@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11132</name>
      <address>
        <city>Newmarket</city>
        <zip>L3Y5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 (905) 898-2931</phone>
      <email>sam@skds.ca; research@skds.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11131</name>
      <address>
        <city>Toronto</city>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 (514) 398-6907</phone>
      <email>liam.durcan@mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 40030</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>petra.keski-santti@terveystalo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 40031</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+358 408 613 444</phone>
      <email>mikko.karppa@oulu.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 40029</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+35-840-078-8020</phone>
      <email>markku.nissila@terveystalo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32666</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 30 450 560 274</phone>
      <email>uwe.reuter@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32667</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 234 158 66</phone>
      <email>philipp@stude.de; philipp.stude@bergmannsheil.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32660</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49-201-436-9624</phone>
      <email>hans.diener@uk-eshans.diener@uni-duisburg-essen.de; h.diener@uni-essen.de;kontakt@ms-center-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32665</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 407 410 59 189</phone>
      <email>a.may@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32662</name>
      <address>
        <city>Kiel</city>
        <zip>24149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49-431-200-99-100</phone>
      <email>hg@schmerzklinik.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32661</name>
      <address>
        <city>Konigstein im Taunus</city>
        <zip>61462</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 617 429 040</phone>
      <email>c.gaul@migraene-klinik.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32663</name>
      <address>
        <city>Rostock</city>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 381 494 4768</phone>
      <email>tim.juergens@med.uni-rostock.de; t.juergens@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80124</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972-8-6745117</phone>
      <email>rmilo@barzi.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80122</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+972 4 630 4262</phone>
      <email>yaronr@hy.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80125</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+972-3-502-82-73</phone>
      <email>y_lampl@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80121</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972 2 6777522</phone>
      <email>e_linetsky@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80123</name>
      <address>
        <city>Netanya</city>
        <zip>42150</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+972-508950084</phone>
      <email>daoved@laniado.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80120</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262160</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+972-5-266-68-175</phone>
      <email>yelena.feingold@sheba.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80127</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mosek@tlvmc.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80126</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>6812509</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+972 3 795 2438</phone>
      <email>vainstein@walla.co.il;vainstein_ga@mac.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30190</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+39 2 239 42 304</phone>
      <email>massimo.leone@istituto-besta.it; leone@istituto-besta.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30192</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+39 5 942 24 211</phone>
      <email>centrocefalee@unimore.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30194</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+39 81 566 5095</phone>
      <email>gioacchino.tedeschi@unina2.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30193</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+39 382 380 425</phone>
      <email>cristina.tassorelli@mondino.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30191</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+39 6 337 75 111</phone>
      <email>paolo.martelletti@uniroma1.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30189</name>
      <address>
        <city>Rome</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+39-06-52252477</phone>
      <email>piero.barbanti@sanraffaele.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 38118</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+31 71 526 2895</phone>
      <email>m.d.ferrari@lumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 38119</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>﻿﻿+31-243-658-765</phone>
      <email>w.mulleners@cwz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 38117</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+31 38 424 2458</phone>
      <email>j.s.p.van.den.berg@isala.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53380</name>
      <address>
        <city>Bialystok</city>
        <zip>15-402</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48-85-748-8438</phone>
      <email>kochanowicz@vp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53383</name>
      <address>
        <city>Krakow</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48 60 262 8121</phone>
      <email>andrzej.szczudlik@neurologia.org.pl; neurologia@cm-uj.krakow.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53379</name>
      <address>
        <city>Krakow</city>
        <zip>33-332</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48 126 563 141</phone>
      <email>martabanach@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53382</name>
      <address>
        <city>Lodz</city>
        <zip>90-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48 514 415 154</phone>
      <email>jacek.rozniecki@umed.lodz.pl; jjrozniecki@afazja.am.lodz.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53381</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48-918-136-322</phone>
      <email>marcin.ratajczak@euromedis.pl; marcin.ratajczak@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31211</name>
      <address>
        <city>Galdakao.</city>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 944 007 234</phone>
      <email>hospit05@sarenet.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31214</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 91 387 5250</phone>
      <email>msanchezd@unav.es; msanchezdelrio@ruberinternational.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31213</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 955 923 000</phone>
      <email>mjimenez@us.es; carmengoria@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31212</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34-983-420-000</phone>
      <email>gueneurol@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31215</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 976 768 873</phone>
      <email>ssantos@salud.aragon.es; ssantosl@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 42047</name>
      <address>
        <city>Huddinge</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+46 8 585 80 000</phone>
      <email>ingela.nilsson-remahl@sll.se; ingela.nilsson-remahl@karolinska.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 42045</name>
      <address>
        <city>Vallingby</city>
        <zip>162 68</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+46 858 080 333</phone>
      <email>bo.liu@s3smo.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34224</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 1 41 232 7542</phone>
      <email>aloktyagi@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34220</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 20 331 211 45</phone>
      <email>richard.peatfield@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34223</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 20 329 96 384</phone>
      <email>peter.goadsby@kcl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34221</name>
      <address>
        <city>Oxford</city>
        <zip>OX2 6HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 186 523 1894</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Cluster Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

